HTG, Sanofi Collaborating to Identify B- Cell Response Markers for Cancer Drug | GenomeWeb
A biomarker discovery collaboration between HTG Molecular Diagnostics and Sanofi US will use HTG’s quantitative nucleic acid protection, or qNPA, technology to identify molecular targets in white blood cells associated with response to an unnamed cancer drug.